R&D Pipeline

R&D Pipeline

Guided by innovation and internationalization, Fosun Pharma increases its investment in R&D and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its R&D and clinical trial capacities for new drugs, and speeds up the R&D and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent R&D, co-development, in-licensing, and in-depth incubation.

Major Drugs under Development

We have established efficient international R&D teams in China, the United States, India and other countries

0

Self-developed small molecule innovator drug

0

Self-developed innovative biologics

0

In-licensing innovator drugs

0

Self-developed biosimilars

Updated to March 31, 2024

Oncology

Non-oncology

ProductTargetIndicationPre-
clinical
INDPhase IPhase IIPhase IIINDAApproved for
Marketing
Development Progress
in Other Areas
FS-1502HER2Breast cancer        
Gastric cancer/
Gastroesophageal
junction adenocarcinoma
        
FS-1502+HLX10HER2/PD-1Advanced gastric
cancer with HER2+
        
HLX208BRAF V600ESolid Tumor        
HLX208+HLX10BRAF V600E/PD-1Solid Tumor        
HLX22+HLX02HER2/HER2Gastric cancer        
SurVaxMSURVIVINNewly diagnosed glioblastoma        
Comirnaty (COVID-19 Vaccine, mRNA)Spike protein (S protein)COVID-19       Hong Kong, China:
Adult type approved
for marketing
Macau, China: Adult type approved for marketing
Avatrombopag
Maleate
Tablets Doptelet®
TPO receptor
agonist
Chronic immune
thrombocytopenia
        
RT002/Moderate to severe glabellar lines in adults        
Isolated cervical dystonia        
PA-824 (Pretomanid Tablets)/Tuberculosis (MDR-TB)       Approved for marketing
in Hong Kong of China
TenapanorNHE3End-stage renal disease
with hyperphosphatemia
        
Constipation-predominant
irritable bowel syndrome
       Approved for marketing
in Hong Kong of China
Fortacin/Premature ejaculation        
OpicaponeCOMT inhibitorParkinsonian syndrome        
OP0595 (Nacubactam) + Cefepime or AztreonamBeta-lactamase inhibitorInfection due to
aerobic Gram-negative
bacteria with limited
treatment options
in adults
       Phase III MRCT
Grafalon Fu Ke Shu®/Prophylaxis of graft
versus host disease
(GvHD), after
hematopoietic stem
cell transplantation